New Treatment Approaches for the Anemia of CKD

American Journal of Kidney Diseases

Volumn 67, Issue 1, 2016, Pages 133-142

  Bonomini, Mario ^a   Del Vecchio, Lucia ^b   Sirolli, Vittorio ^a   Locatelli, Francesco ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b A MANZONI HOSPITAL   (Italy)

Author keywords

activin trap; Chronic kidney disease (CKD); chronic renal insufficiency; dialysis; end stage renal disease; EPO receptor; erythropoiesis; erythropoiesis stimulating agent (ESA); erythropoietin (EPO); gene therapy; HIF stabilizer; hypoxia inducible factor (HIF); prolyl hydroxylase inhibitor; renal anemia; review

Indexed keywords

2 OXOGLUTARIC ACID; ABT 007; ACTIVIN; ANTIANEMIC AGENT; CNTO 530; CNTO 531; DAPRODUSTAT; DS 1093A; GALUNISERTIB; GLUCOSE; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; IMMUNOGLOBULIN G1 ANTIBODY; JTZ 951; LUSPATERCEPT; MOLIDUSTAT; NEW DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; ROXADUSTAT; SOTATERCEPT; UNCLASSIFIED DRUG; VADADUSTAT; VASCULOTROPIN; ERYTHROPOIETIN RECEPTOR;

BETA THALASSEMIA; BLOOD TRANSFUSION; CHOLESTEROL METABOLISM; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DRUG SAFETY; ELIMINATION HALF-LIFE; ERYTHROPOIESIS; GENE THERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; OSTEOLYSIS; OSTEOPOROSIS; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; ANEMIA; COMPLICATION; DRUG EFFECTS;

ACTIVINS; ANEMIA; HEMATINICS; HUMANS; RECEPTORS, ERYTHROPOIETIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84955194066     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.06.030     Document Type: Review

References (103)

1. A.T. Kausz, and A.S. Levey The care of patients with chronic kidney disease J Gen Intern Med 17 8 2002 658 662
2. C.G. Winearls, D.O. Oliver, M.J. Pippard, C. Reid, M.R. Downing, and P.M. Cotes Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis Lancet 2 8517 1986 1175 1178
3. W. Jelkmann The ESA scenario gets complex: from biosimilar epoetins to activin traps Nephrol Dial Transplant 30 4 2015 553 559
4. A.K. Singh, L. Szczech, K.L. Tang, and et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
5. T.B. Drüeke, F. Locatelli, N. Clyne, and et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
6. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, and et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
7. R.L. Pisoni, D.S. Fuller, B.A. Bieber, and et al. The DOPPS Practice Monitor for US dialysis care: trends through August 2011 Am J Kidney Dis 60 1 2012 160 165
8. KDIGO Anemia Work Group KDIGO clinical practice guideline for anemia in chronic kidney disease Kidney Int Suppl 2 2012 S279 S335
9. F. Locatelli, P. Bárány, A. Covic, et al. ERA-EDTA ERBP Advisory Board Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement Nephrol Dial Transplant 28 6 2013 1346 1359
10. S.C. Hung, and D.C. Tarng ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Kidney Int 86 4 2014 676 678
11. P. Sathyanarayana, E. Houde, D. Marshall, and et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools Blood 113 20 2009 4955 4962
12. P.J. Bugelski, D. Makropoulos, T. Spinka-Doms, and et al. Differential effects of long-lived erythropoietin receptor agonists in rats Pharm Anal Acta 2 7 2011 133
13. A. Greindl, C. Kessler, B. Breuer, and et al. AGEM400(HES), a novel erythropoietin mimetic peptide conjugated to hydroxyethyl starch with excellent in vitro efficacy Open Hematol J 4 2010 1 14
14. C. Kessler, A. Greindl, B. Breuer, and et al. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities Cytokine 57 2 2012 226 237
15. B. Dalle, A. Henri, P. Rouyer-Fessard, and et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo Blood 97 12 2001 3776 3782
16. A.J. Sytkowski, E.D. Lunn, M.A. Risinger, and K.L. Davis An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties J Biol Chem 274 35 1999 24773 24778
17. F.A. Fares, S. Ganem, T. Hajouj, and E. Agai Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin Endocrinology 48 10 2007 5081 5087
18. F. Fares, A. Havron, and E. Fima Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin β subunit to the n-terminal coding sequence Int J Cell Biol 2011 2011 275063
19. K. Schriebl, E. Trummer, C. Lattenmayer, and et al. Biochemical characterization of rhEPO-Fc fusion protein expressed in CHO cells Protein Expr Purif 49 2 2006 265 275
20. C.A. Penno, Y. Kawabe, A. Ito, and M. Kamihita Production of recombinant human erythropoietin/Fc fusion protein by genetically manipulated chickens Transgenic Res 19 2 2010 187 195
21. C.H. Joung, J.Y. Shin, J.K. Koo, and et al. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell Protein Expr Purif 68 2 2009 137 145
22. H. Schneider, W. Chaovapong, D.J. Matthews, and et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors Blood 89 2 1997 473 482
23. S. Elliott, T. Lorenzini, D. Yanagihara, D. Chang, and G. Elliott Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies J Biol Chem 271 40 1996 24691 24697
24. S.E. Lacy, P.J. DeVries, N. Xie, E. Fung, R.R. Lesniewski, and E.B. Reilly The potency of erythropoietin-mimic antibodies correlates inversely with affinity J Immunol 181 2 2008 1282 1287
25. N. Suzuki, H.Y. Mukai, and M. Yamamoto In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain PLoS One 10 3 2015 e0119442
26. V.H. Haase Regulation of erythropoiesis by hypoxia-inducible factors Blood Rev 27 1 2013 41 53
27. G.L. Semenza Hypoxia-inducible factors in physiology and medicine Cell 148 3 2012 399 408
28. P.P. Kapitsinou, Q. Liu, T.L. Unger, and et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia Blood 116 16 2010 3039 3048
29. M. Scortegagna, K. Ding, Q. Zhang, and et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner Blood 105 8 2005 3133 3140
30. M. Mastrogiannaki, P. Matak, B. Keith, M.C. Simon, S. Vaulont, and C. Peyssonnaux HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice J Clin Invest 119 5 2009 1159 1166
31. A.J. Majmundar, W.J. Wong, and M.C. Simon Hypoxia-inducible factors and the response to hypoxic stress Mol Cell 40 2 2010 294 309
32. M.H. Rabinowitz Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses J Med Chem 56 23 2013 9369 9402
33. A. Kato, A. Hishida, H. Kumagai, R. Furuya, T. Nakajima, and N. Honda Erythropoietin production in patients with chronic renal failure Ren Fail 16 5 1994 645 651
34. S. Shimizu, Y. Enoki, S. Sakata, H. Kohzuki, Y. Ohga, and K. Matsumura Erythropoietin response to acute hypobaric or anaemic hypoxia in gentamicin-administered rats Acta Physiol Scand 151 2 1994 225 231
35. A. Priyadarshi, S. Periyasamy, T.J. Burke, S.L. Britton, D. Malhotra, and J.I. Shapiro Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rat Kidney Int 61 2 2002 542 546
36. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis stimulating agents - time for a reevaluation N Engl J Med 362 3 2010 189 192
37. A. Besarab, E.N. Chernyavskaya, I. Motylev, and et al. FG-4592, an oral hypoxia-inducible factor propyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients [ASN abstract TH-OR096] J Am Soc Nephrol 23 2012 21A
38. Provenzano R, Goodkin D, Klaus S, et al. Evaluation of FG-4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients [abstract 188]. Presented at: National Kidney Foundation Conference; April 26-30, 2011; Las Vegas, NV.
39. K.E. Finberg Regulation of systemic iron homeostasis Curr Opin Hematol 20 3 2013 208 214
40. C.C. Sun, V. Vaja, J.L. Babitt, and H.Y. Lin Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation Am J Hematol 87 4 2012 392 400
41. J.Q. Qian, N. Chen, J. Chen, and et al. A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China [ASN abstract FR-OR011] J Am Soc Nephrol 24 2013 38A
42. A. Besarab, D. Tak Mao Chan, S.L. Dua, and et al. Hypoxia inducing factor propyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis [ASN abstract SA-OR087] J Am Soc Nephrol 24 2013 91A
43. Akebia announces positive top-line results from its phase 2b study of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease. http://ir.akebia.com/releasedetail.cfm?ReleaseID=878191. Accessed March 2, 2015.
44. A phase IIa, randomized, single-blind, placebo-controlled, parallel-group study to evaluate the safety, pharmacokinetics, and efficacy of 28-day repeat oral doses of GSK 1278863A in anemic pre-dialysis and hemodialysis-dependent patients. GlaxoSmithKline website www.gsk-clinicalstudyregister.com/study/112844#rs. Accessed March 2, 2015.
45. A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in normal subjects and subjects with impaired renal function. GlaxoSmithKline website www.gsk-clinicalstudyregister.com/study/115573#rs. Accessed March 2, 2015.
46. Studies filtered by compound GSK 1278863. GlaxoSmithKline website www.gsk-clinicalstudyregister.com/compounds/gsk1278863#ps. Accessed March 2, 2015.
47. I. Flamme, F. Oehme, P. Ellinghaus, M. Jeske, J. Keldenich, and U. Thuss Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects PLoS One 9 11 2014 e111838
48. M.F. Boettcher, S. Lentini, A. Kaiser, I. Flamme, D. Kubitza, and G. Wensing First-in-man study with BAY 85-3934 - a new oral selective HIF-PH inhibitor for the treatment of renal anemia [ASN abstract THPO1090] J Am Soc Nephrol 24 2013 347A
49. Safety, tolerability, PK and PD study of JTZ-951 in anemic subjects with end-stage renal disease. U.S. National Institutes of Health website https://clinicaltrials.gov/ct2/show?term=jtz-951&rank=2. Accessed March 2, 2015.
50. Pilot PK/PD study of DS-1093a in patients with chronic kidney disease. U.S. National Institutes of Health website https://clinicaltrials.gov/ct2/show?term=ds-1093a&rank=1. Accessed March 2, 2015.
51. K. Cheng, K. Ho, R. Stokes, and et al. Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets J Clin Invest 120 6 2010 2171 2183
52. E.B. Rankin, J. Rha, M.A. Selak, and et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism Mol Cell Biol 29 16 2009 4527 4538
53. J. Zehetner, C. Danzer, S. Collins, and et al. PVHL is a regulator of glucose metabolism and insulin secretion in pancreatic beta cells Genes Dev 22 22 2008 3135 3146
54. J. Krishnan, M. Suter, R. Windak, and et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy Cell Metab 9 6 2009 512 524
55. G.L. Semenza HIF-1: upstream and downstream of cancer metabolism Curr Opin Genet Dev 20 1 2009 51 56
56. P.J. Ratcliffe Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer J Physiol 591 8 2013 2027 2042
57. S.F. Rimoldi, E. Rexhaj, L. Pratali, and et al. Systemic vascular dysfunction in patients with chronic mountain sickness Chest 141 1 2012 139 146
58. J.P. Schmid, D. Nobel, N. Brugger, and et al. Short-term high altitude exposure at 3454m is well tolerated in patients with stable heart failure Eur J Heart Fail 17 2 2015 182 186
59. 2+ exchanger in developing rats Cell Physiol Biochem 34 2 2014 313 324
60. V. Maguer-Satta, L. Bartholin, S. Jeanpierre, and et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family Exp Cell Res 282 2 2003 110 120
61. J. Yu, L. Maderazo, L.E. Shao, and et al. Specific roles of activin/inhibin in human erythropoiesis in vitro Ann N Y Acad Sci 628 1991 199 211
62. Y. Zermati, S. Fichelson, F. Valensi, and et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors Exp Hematol 28 8 2000 885 894
63. M. Murata, Y. Eto, H. Shibai, M. Sakai, and M. Muramatsu Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain Proc Natl Acad Sci U S A 85 8 1988 2434 2438
64. N. Raje, and S. Vallet Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss Curr Opin Mol Ther 12 5 2010 586 597
65. J. Ruckle, M. Jacobs, W. Kramer, and et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women J Bone Miner Res 24 4 2009 744 752
66. K. Abdulkadyrov, G. Salogub, N. Khuazheva, and et al. ACE-011, a soluble activin receptor type IIa IgG-FC fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis Blood 114 22 2009 (ASH Annual Meeting Abstracts):Abstract 749
67. J. Yu, L. Shao, J. Vaughan, W. Vale, and A.L. Yu Characterization of the potentiation effect of activin on human erythroid colony formation in vitro Blood 73 4 1989 952 960
68. l Shao, N.L. Frigon Jr., A.L. Young, and et al. Effect of activin A on globin gene expression in purified human erythroid progenitors Blood 79 3 1992 773 781
69. C. Iancu-Rubin, G. Mosoyan, J. Wang, T. Kraus, V. Sung, and R. Hoffman Stromal cell-mediated inhibition of erythropoiesis can be attenuated by sotatercept (ACE-011), an activin receptor type II ligand trap Exp Hematol 41 2013 155 166
70. U. Blank, and S. Karlsson The role of Smad signaling in hematopoiesis and translational hematology Leukemia 25 9 2011 1379 1388
71. M. El-Shahawy, J. Cotton, J. Kaupke, N. Kopyt, S. Choi, and W.T. Smith Safety and hemoglobin effects of the first 28-day dose cycle of sotatercept 0.7 mg/kg compared with lower doses and placebo for correction of anemia in hemodialysis subjects: interim analysis [ASN abstract TH-PO985] J Am Soc Nephrol 25 2014 337A
72. C. Besson-Fournier, C. Latour, L. Kautz, and et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling Blood 120 2 2012 431 439
73. K.E. Finberg, R.L. Whittlesey, M.D. Fleming, and N.C. Andrews Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis Blood 115 18 2010 3817 3826
74. J. Truksa, P. Lee, and E. Beutler Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness Blood 113 3 2009 688 695
75. T. Ganz Systemic iron homeostasis Physiol Rev 93 4 2013 1721 1741
76. S. Lotinun, R.S. Pearsall, W.C. Horne, and R. Baron Activin receptor signaling: a potential therapeutic target for osteoporosis Curr Mol Pharmacol 5 2 2012 195 204
77. S. Lotinun, R.S. Pearsall, M.V. Davies, and et al. A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys Bone 46 4 2010 1082 1088
78. R.S. Pearsall, E. Canalis, M. Cornwall-Brady, and et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity Proc Natl Acad Sci U S A 105 19 2008 7082 7087
79. Y. Fang, O.A. Agapova, T. Sugatani, H. Malluche, and K.A. Hruska Treatment of the CKD-MBD with a ligand trap for the activin receptor type 2A [ASN abstract FR-PO816] J Am Soc Nephrol 25 2014 557A
80. K.A. Hruska, O.A. Agapova, Y. Fang, T. Sugatani, M.E. Seifert, and V. Sung Chronic kidney disease (CKD) stimulates activin and endothelial to mesenchymal transition (EnMT), which causes vascular calcification and is inhibited by an activin ligand trap [ASN abstract SA-OR063] J Am Soc Nephrol 25 2014 95A
81. M.B. Leonard A structural approach to skeletal fragility in chronic kidney disease Semin Nephrol 29 2 2009 133 143
82. H. Malluche, K. Hurska, H.N. Singh, and W.T. Smith Sotatercept: initial signal-seeking quantitative computed tomography results for bone mass and vascular calcification in hemodialysis patients treated with escalating doses: interim analysis of ACE-011-REN-001 [ASN abstract TH-PO602] J Am Soc Nephrol 25 2014 245A
83. R.N. Suragani, S.M. Cadena, S.M. Cawley, and et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis Nat Med 20 4 2014 408 414
84. K.M. Attie, M.J. Allison, T. McClure, and et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers Am J Hematol 89 7 2014 766 770
85. O. Livnah, E.A. Stura, and D.L. Johnson Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A Science 273 5274 1996 464 471
86. N.C. Wrighton, F.X. Farrell, R. Chang, and et al. Small peptides as potent mimetics of the protein hormone erythropoietin Science 273 5274 1996 458 464
87. D.L. Johnson, F.X. Farrell, F.P. Barbone, and et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1 Biochemistry 37 11 1998 3699 3710
88. C. Huang Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology Curr Opin Biotechnol 20 6 2009 692 699
89. E. Bouman-Thio, K. Franson, B. Miller, and et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects J Clin Pharmacol 48 10 2008 1197 1207
90. J.J. Perez-Ruixo, W. Krzyzanski, E. Bouman-Thio, and et al. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects Clin Pharmacokinet 48 9 2009 601 613
91. I.C. Macdougall, R. Provenzano, A. Sharma, and et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis N Engl J Med 368 4 2013 320 332
92. S. Fishbane, B. Schiller, F. Locatelli, and et al. Peginesatide in patients with anemia undergoing hemodialysis N Engl J Med 368 4 2013 307 319
93. I.C. Macdougall, J. Rossert, N. Casadevall, and et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia N Engl J Med 361 19 2009 1848 1855
94. Affimax and Takeda announce a nationwide voluntary recall of all lots of OMONTYSR (peginesatide) Injection. http://www.takeda.com/news/2013/20130224-5664.html. Accessed February 8, 2015.
95. S.J. Im, S.I. Yang, S.H. Yang, and et al. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin PLoS One 6 2011 e24574
96. K.H. Roux, L. Strelets, O.H. Brekke, I. Sandlie, and T.E. Michaelsen Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry J Immunol 161 8 1998 4083 4090
97. E.E. Idusogie, P.Y. Wong, L.G. Presta, and et al. Engineered antibodies with increased activity to recruit complement J Immunol 166 4 2001 2571 2575
98. J. Schuurman, G.J. Perdok, A.D. Gorter, and R.G. Aalberse The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds Mol Immunol 38 1 2001 1 8
99. S.H. Yang, S.I. Yang, and Y.-K. Chung A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia Arch Pharm Res 35 5 2012 757 759
100. Study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of GX-E2 in healthy subjects (GX-E2-P1). U.S. National Institutes of Health website https://clinicaltrials.gov/ct2/show/study/NCT02291991?term=GX-E2&rank=.1 Accessed March 2, 2015.
101. Study to evaluate the efficacy and safety of GX-E2 in the anemic patients diagnosed with chronic kidney disease (CKD). U.S. National Institutes of Health website https://clinicaltrials.gov/ct2/show/study/NCT02044653?term=GX-E2&rank=2. Accessed March 2, 2015.
102. E. Brill-Almon, B. Stern, D. Afik, and et al. Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins Mol Ther 12 2 2005 274 282
103. Neil G. Prolonged secretion of physiological levels of autologous EPO by TARGT. Presented at: XXII Annual Congress of the European Society of Gene and Cell Therapy; The Hague, the Netherlands; October 23-26, 2014.